Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde.

NADP(H)-dependent cytosolic aldo-keto reductases (AKR) are mostly monomeric enzymes which fold into a typical (α/β)(8)-barrel structure. Substrate specificity and inhibitor selectivity are determined by interaction with residues located in three highly variable loops (A, B, and C). Based on sequence identity, AKR have been grouped into families, namely AKR1-AKR15, containing multiple subfamilies. Two human enzymes from the AKR1B subfamily (AKR1B1 and AKR1B10) are of special interest. AKR1B1 (aldose reductase) is related to secondary diabetic complications, while AKR1B10 is induced in cancer cells and is highly active with all-trans-retinaldehyde. Residues interacting with all-trans-retinaldehyde and differing between AKR1B1 and AKR1B10 are Leu125Lys and Val131Ala (loop A), Leu301Val, Ser303Gln, and Cys304Ser (loop C). Recently, we demonstrated the importance of Lys125 as a determinant of AKR1B10 specificity for retinoids. Residues 301 and 304 are also involved in interactions with substrates or inhibitors, and thus we checked their contribution to retinoid specificity. We also extended our study with retinoids to rodent members of the AKR1B subfamily: AKR1B3 (aldose reductase), AKR1B7 (mouse vas deferens protein), AKR1B8 (fibroblast-growth factor 1-regulated protein), and AKR1B9 (Chinese hamster ovary reductase), which were tested against all-trans isomers of retinaldehyde and retinol. All enzymes were active with retinaldehyde, but with k(cat) values (0.02-0.52 min(-1)) much lower than that of AKR1B10 (27 min(-1)). None of the enzymes showed oxidizing activity with retinol. Since these enzymes (except AKR1B3) have Lys125, other residues should account for retinaldehyde specificity. Here, by using site-directed mutagenesis and molecular modeling, we further delineate the contribution of residues 301 and 304. We demonstrate that besides Lys125, Ser304 is a major structural determinant for all-trans-retinaldehyde specificity of AKR1B10.

[1]  Hiroyuki Aburatani,et al.  Overexpression of the Aldo-Keto Reductase Family Protein AKR1B10 Is Highly Correlated with Smokers' Non–Small Cell Lung Carcinomas , 2005, Clinical Cancer Research.

[2]  J. Winkles,et al.  A delayed-early gene activated by fibroblast growth factor-1 encodes a protein related to aldose reductase. , 1994, The Journal of biological chemistry.

[3]  S. Hirohashi,et al.  Combined Functional Genome Survey of Therapeutic Targets for Hepatocellular Carcinoma , 2010, Clinical Cancer Research.

[4]  O. El-Kabbani,et al.  Characterization of a rat NADPH-dependent aldo-keto reductase (AKR1B13) induced by oxidative stress. , 2009, Chemico-biological interactions.

[5]  T. Flynn,et al.  Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. , 2003, The Biochemical journal.

[6]  R. Crystal,et al.  Smoking-induced upregulation of AKR1B10 expression in the airway epithelium of healthy individuals. , 2010, Chest.

[7]  M. Lewis,et al.  Comparative anatomy of the aldo-keto reductase superfamily. , 1997, The Biochemical journal.

[8]  Elena V Shabrova,et al.  Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/reductases and aldo-keto reductases with retinoids. , 2006, The Biochemical journal.

[9]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[10]  O. El-Kabbani,et al.  Rat aldose reductase-like protein (AKR1B14) efficiently reduces the lipid peroxidation product 4-oxo-2-nonenal. , 2010, Biological & pharmaceutical bulletin.

[11]  C. Yabe-Nishimura,et al.  Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. , 1998, Pharmacological reviews.

[12]  O. El-Kabbani,et al.  Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid. , 2010, Biological & pharmaceutical bulletin.

[13]  A. Bhatnagar,et al.  Kinetic studies of FR-1, a growth factor-inducible aldo-keto reductase. , 1998, Biochemistry.

[14]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[15]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules J. Am. Chem. Soc. 1995, 117, 5179−5197 , 1996 .

[16]  O. El-Kabbani,et al.  Properties and tissue distribution of a novel aldo-keto reductase encoding in a rat gene (Akr1b10). , 2010, Archives of biochemistry and biophysics.

[17]  T. Flynn,et al.  Cloning, Sequencing, and Enzymatic Activity of an Inducible Aldo-Keto Reductase from Chinese Hamster Ovary Cells* , 1997, The Journal of Biological Chemistry.

[18]  A. Bhatnagar,et al.  The Aldo-Keto Reductase Superfamily and its Role in Drug Metabolism and Detoxification , 2008, Drug metabolism reviews.

[19]  Trevor M Penning,et al.  Aldo-keto reductase (AKR) superfamily: Genomics and annotation , 2009, Human Genomics.

[20]  T. Tanimoto,et al.  Presence of a closely related subgroup in the aldo-ketoreductase family of the mouse. , 1995, European journal of biochemistry.

[21]  Jean-Michel Claverie,et al.  Phylogeny.fr: robust phylogenetic analysis for the non-specialist , 2008, Nucleic Acids Res..

[22]  T. Flynn,et al.  A new nomenclature for the aldo-keto reductase superfamily. , 1997, Biochemical pharmacology.

[23]  H. Jörnvall,et al.  A Vertebrate Aldo-keto Reductase Active with Retinoids and Ethanol* , 2001, The Journal of Biological Chemistry.

[24]  T. Penning,et al.  Oxidation of PAH trans-dihydrodiols by human aldo-keto reductase AKR1B10. , 2008, Chemical research in toxicology.

[25]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[26]  D. Tritsch,et al.  Product of Side-chain Cleavage of Cholesterol, Isocaproaldehyde, Is an Endogenous Specific Substrate of Mouse Vas Deferens Protein, an Aldose Reductase-like Protein in Adrenocortical Cells* , 1999, The Journal of Biological Chemistry.

[27]  G. Balendiran,et al.  Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. , 2008, European journal of pharmacology.

[28]  G. Levan,et al.  Characterization of the aldose reductase-encoding gene family in rat. , 1991, Gene.

[29]  Sheung Tat Fan,et al.  Identification and Characterization of a Novel Human Aldose Reductase-like Gene* , 1998, The Journal of Biological Chemistry.

[30]  E. Pailhoux,et al.  Androgen-dependent protein from mouse vas deferens. cDNA cloning and protein homology with the aldo-keto reductase superfamily. , 1990, The Journal of biological chemistry.

[31]  O. El-Kabbani,et al.  Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening. , 2010, European journal of medicinal chemistry.

[32]  O. El-Kabbani,et al.  Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis. , 2009, Biochemical and biophysical research communications.

[33]  Trevor M Penning,et al.  AKR1B10: A New Diagnostic Marker of Non–Small Cell Lung Carcinoma in Smokers , 2005, Clinical Cancer Research.

[34]  S. Chung,et al.  Tissue-specific expression of two aldose reductase-like genes in mice: abundant expression of mouse vas deferens protein and fibroblast growth factor-regulated protein in the adrenal gland. , 1995, The Biochemical journal.

[35]  Yi Jin,et al.  Aldo-keto reductases and bioactivation/detoxication. , 2007, Annual review of pharmacology and toxicology.

[36]  A. Bhatnagar,et al.  Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes. , 2007, The Biochemical journal.

[37]  R. Álvarez,et al.  Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels. , 2009, Chemico-biological interactions.

[38]  Angel R de Lera,et al.  Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10 , 2007, Proceedings of the National Academy of Sciences.